Ken Griffin’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.75M | Sell |
23,415
-15,044
| -39% | -$5.12M | ﹤0.01% | 3628 |
|
|
2025
Q4 | $15.3M | Sell |
38,459
-183,384
| -83% | -$81.2M | ﹤0.01% | 2679 |
|
|
2025
Q3 | $101M | Sell |
221,843
-379,356
| -63% | -$154M | 0.02% | 837 |
|
|
2025
Q2 | $196M | Buy |
601,199
+596,963
| +14,093% | +$165M | 0.03% | 418 |
|
|
2025
Q1 | $1.14M | Sell |
4,236
-61,157
| -94% | -$15.7M | ﹤0.01% | 6671 |
|
|
2024
Q4 | $15.4M | Buy |
65,393
+41,461
| +173% | +$10.9M | ﹤0.01% | 2453 |
|
|
2024
Q3 | $6.58M | Sell |
23,932
-343,357
| -93% | -$89.4M | ﹤0.01% | 3512 |
|
|
2024
Q2 | $89.3M | Buy |
367,289
+327,305
| +819% | +$51.7M | 0.02% | 748 |
|
|
2024
Q1 | $5.98M | Sell |
39,984
-26,665
| -40% | -$4.45M | ﹤0.01% | 3659 |
|
|
2023
Q4 | $12.8M | Buy |
+66,649
| New | +$11.4M | ﹤0.01% | 2533 |
|
|
2023
Q3 | – | Sell |
-29,563
| Closed | -$5.64M | – | 14231 |
|
|
2023
Q2 | $5.62M | Sell |
29,563
-74,773
| -72% | -$14.8M | ﹤0.01% | 3472 |
|
|
2023
Q1 | $20.9M | Buy |
104,336
+102,896
| +7,146% | +$21.6M | ﹤0.01% | 1876 |
|
|
2022
Q4 | $342K | Sell |
1,440
-81,132
| -98% | -$17.3M | ﹤0.01% | 9025 |
|
|
2022
Q3 | $16.5M | Buy |
82,572
+74,878
| +973% | +$14.3M | ﹤0.01% | 2101 |
|
|
2022
Q2 | $1.12M | Buy |
7,694
+5,586
| +265% | +$792K | ﹤0.01% | 6761 |
|
|
2022
Q1 | $344K | Sell |
2,108
-68,660
| -97% | -$10.5M | ﹤0.01% | 10276 |
|
|
2021
Q4 | $12M | Buy |
70,768
+49,889
| +239% | +$9.27M | ﹤0.01% | 2759 |
|
|
2021
Q3 | $3.94M | Sell |
20,879
-18,070
| -46% | -$3.39M | ﹤0.01% | 4779 |
|
|
2021
Q2 | $6.6M | Sell |
38,949
-84,277
| -68% | -$12.3M | ﹤0.01% | 3865 |
|
|
2021
Q1 | $17.4M | Buy |
123,226
+42,265
| +52% | +$6.36M | ﹤0.01% | 2146 |
|
|
2020
Q4 | $10.5M | Buy |
80,961
+54,428
| +205% | +$7.27M | ﹤0.01% | 2579 |
|
|
2020
Q3 | $3.86M | Sell |
26,533
-47,167
| -64% | -$6.7M | ﹤0.01% | 3540 |
|
|
2020
Q2 | $10.9M | Sell |
73,700
-36,658
| -33% | -$4.94M | ﹤0.01% | 2116 |
|
|
2020
Q1 | $12M | Buy |
110,358
+29,585
| +37% | +$3.41M | 0.01% | 1677 |
|
|
2019
Q4 | $9.3M | Buy |
80,773
+367
| +0.5% | +$36.6K | ﹤0.01% | 2288 |
|
|
2019
Q3 | $6.47M | Sell |
80,406
-885,638
| -92% | -$70.1M | ﹤0.01% | 2757 |
|
|
2019
Q2 | $70.1M | Buy |
966,044
+953,740
| +7,751% | +$73.2M | 0.03% | 553 |
|
|
2019
Q1 | $1.15M | Sell |
12,304
-17,316
| -58% | -$1.45M | ﹤0.01% | 5349 |
|
|
2018
Q4 | $2.16M | Sell |
29,620
-5,856
| -17% | -$450K | ﹤0.01% | 4024 |
|
|
2018
Q3 | $3.1M | Sell |
35,476
-1,212
| -3% | -$122K | ﹤0.01% | 3679 |
|
|
2018
Q2 | $3.61M | Buy |
+36,688
| New | +$3.64M | ﹤0.01% | 3229 |
|
|
2018
Q1 | – | Sell |
-57,507
| Closed | -$7.41M | – | 8225 |
|
|
2017
Q4 | $7.31M | Buy |
57,507
+12,286
| +27% | +$1.54M | ﹤0.01% | 2038 |
|
|
2017
Q3 | $5.31M | Buy |
+45,221
| New | +$3.86M | ﹤0.01% | 2250 |
|
|
2017
Q1 | – | Sell |
-9,632
| Closed | -$445K | – | 7385 |
|
|
2016
Q4 | $361K | Buy |
+9,632
| New | +$403K | ﹤0.01% | 5409 |
|
|
2016
Q2 | – | Sell |
-730,736
| Closed | -$46M | – | 6774 |
|
|
2016
Q1 | $45.9M | Buy |
730,736
+549,198
| +303% | +$36.5M | 0.06% | 327 |
|
|
2015
Q4 | $17.1M | Buy |
181,538
+42,110
| +30% | +$3.9M | 0.02% | 928 |
|
|
2015
Q3 | $11.2M | Buy |
139,428
+135,409
| +3,369% | +$15M | 0.01% | 1278 |
|
|
2015
Q2 | $482K | Sell |
4,019
-111
| -3% | -$13.3K | ﹤0.01% | 5039 |
|
|
2015
Q1 | $431K | Sell |
4,130
-5,410
| -57% | -$548K | ﹤0.01% | 5139 |
|
|
2014
Q4 | $925K | Sell |
9,540
-241,810
| -96% | -$22.4M | ﹤0.01% | 3865 |
|
|
2014
Q3 | $19.6M | Buy |
251,350
+249,369
| +12,588% | +$16.1M | 0.02% | 918 |
|
|
2014
Q2 | $125K | Sell |
1,981
-24,538
| -93% | -$1.46M | ﹤0.01% | 6035 |
|
|
2014
Q1 | $1.78M | Buy |
+26,519
| New | +$2.05M | ﹤0.01% | 2779 |
|
|
2013
Q4 | – | Sell |
-273,219
| Closed | -$16.3M | – | 6984 |
|
|
2013
Q3 | $17.5M | Sell |
273,219
-914,677
| -77% | -$45.6M | 0.03% | 783 |
|
|
2013
Q2 | $36.8M | Buy |
+1,187,896
| New | +$31.6M | 0.06% | 355 |
|
Other funds holding ALNY
VPM
VCM
Ken Griffin's ALNY Position: Q1 2026 in Review
Ken Griffin reduced its Alnylam Pharmaceuticals (ALNY) stake by 39% in Q1 2026, selling an estimated $5.12M and leaving 23,415 shares worth $7.75M. The position accounts for ﹤0.01% of the portfolio, ranked #3628.
Ken Griffin first reported a position in ALNY in Q2 2013 and has held it in 45 quarters since. The position peaked at $196M in Q2 2025. 789 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Ken Griffin held 23,415 shares of Alnylam Pharmaceuticals worth $7.75M as of Q1 2026.
- Ken Griffin sold 15,044 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $5.12M.
- Alnylam Pharmaceuticals made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #3628 holding.
- Ken Griffin first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 45 quarters since.
- Ken Griffin's Alnylam Pharmaceuticals position peaked at $196M in Q2 2025.
- 789 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.